Gilead SUPHO01-ENHANCEIII AML

Gesloten

Main info

Identificatie:
SUPHO01-ENHANCEIII
Sponsor:
Gilead
Working group party:
Leukemia
Stadium:
1st lijn
Echelon:
Level C-HIC&C-SCT
Included patients:
44
(of 43)
Active sites:
18
(of 19)
4 sites are pending
Title:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Evaluating the Safety and Efficacy of Magrolimab versus Placebo in
Combination with Venetoclax and Azacitidine in Newly Diagnosed,
Previously Untreated Patients with Acute Myeloid Leukemia Who Are
Ineligible for Intensive Chemotherapy

Timeline

Scheduled
Actual
2023
01 feb.
Activated
2023
21 aug.
On Hold
2024
13 feb.
ClosedForInclusionActualStart

News

December 2022:
HOVON is giving support to GILEAD for the conduct of the SUPHO01-ENHANCE III study.
The trial management will be performed by ICON.
However, if you have questions f.i. for the coordinating HOVON investigator G. Huls (UMCG) please contact us.

February 2024:
Following the independent data monitoring committee (iDMC) meeting that occurred on 02 February 2024 for a planned futility analysis based on overall survival (OS), Gilead has decided to terminate the ENHANCE-3 / SUPHO01 study based on the determination of futility.

Details

Phase:
Prospective double-blind randomized phase III study
Monitoring Type:
Study Specific
Objectives:

Participating Sites

Site
22 results
Order by
Accrual rate
Activation date
BE-Liege-CHULIEGE
8
17 nov. 2022
NL-Groningen-UMCG
7
13 dec. 2022
BE-Haine-Saint-Paul-JOLIMONT
5
26 sep. 2022
NO-Oslo-OSLOUH
4
07 nov. 2022
NL-Den Bosch-JBZ
3
23 nov. 2022
CH-Bern-INSEL
2
30 mrt. 2023
NL-Amersfoort-MEANDERMC
2
28 nov. 2022
NL-Leeuwarden-MCL
2
13 dec. 2022
NL-Rotterdam-ERASMUSMC
2
22 nov. 2022
NL-Breda-AMPHIA
2
03 nov. 2022
BE-Antwerpen-ZNASTUIVENBERG
2
29 sep. 2022
BE-Gent-UZGENT
2
13 sep. 2022
NL-Den Haag-HAGA
1
05 dec. 2022
NL-Maastricht-MUMC
1
28 nov. 2022
NL-Amsterdam-VUMC
1
08 nov. 2022
NL-Nijmegen-CWZ
27 dec. 2022
BE-Bruxelles-STLUC
NL-Nieuwegein-ANTONIUS
15 dec. 2022
NL-Enschede-MST
BE-Antwerpen-ZNAMIDDELHEIM
29 sep. 2022
BE-Leuven-UZLEUVEN
CH-Zürich-USZ
= Active hospitals
= Inactive hospitals

Participating Parties

Up